Evotec and Odyssey Therapeutics Join Forces in AI-Driven Drug Discovery

Evotec SE has announced a strategic collaboration with Odyssey Therapeutics to explore new treatments for autoimmune and inflammatory diseases. This partnership will harness Evotec's AI-driven discovery platform alongside Odyssey's expertise in disease biology to develop potential drug candidates.

Evotec will be responsible for delivering validated hit series targeting significant autoimmune and inflammatory diseases. Odyssey aims to advance these small-molecule drug candidates using Evotec’s screening capabilities and compound libraries. The collaboration aspires to expedite early-stage research and rapidly progress therapeutic programs.

Dr. Cord Dohrmann, Evotec's Chief Scientific Officer, emphasized the importance of integrating disease biology with advanced experimental approaches in drug discovery. The partnership is expected to generate differentiated starting points for new treatments, with Evotec eligible for milestone payments based on successful outcomes.